Marius Pharmaceuticals LLC

KYZATREX, developed by Marius Pharmaceuticals, received FDA approval in 2022 as the first oral testosterone replacement therapy utilizing phytosterols for lymphatic absorption.

The FDA has eliminated the cardiovascular black box warning from testosterone replacement therapy products, following conclusive evidence from the 5,000-patient TRAVERSE trial showing no increased cardiovascular risks.